HealthcareServices

Pneumonia Therapeutics Sector Forecast Shows Robust Momentum, Climbing to $18.83 Billion With 10.4% CAGR

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pneumonia therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Pneumonia Therapeutics Market reach by 2030 starting from 2026 levels?

The size of the pneumonia therapeutics market has experienced rapid expansion in recent years. It is projected to increase from $11.46 billion in 2025 to $12.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.7%. This historic period’s growth is largely attributable to the increasing incidence of respiratory infections, rising hospitalization rates for pneumonia, the widespread use of antibiotics, the expansion of intensive care infrastructure, and a growing elderly population.

The pneumonia therapeutics market is projected to experience substantial expansion in the coming years. This market is forecast to reach $18.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This projected growth is driven by factors such as the accelerated development of new antibiotics and antivirals, the increasing uptake of rapid diagnostic testing, an amplified focus on managing antimicrobial resistance, the proliferation of homecare treatment models for pneumonia, and greater investment in vaccine-driven prevention approaches. Key trends anticipated during this period encompass the wider adoption of targeted antimicrobial therapies, an upward trend in the use of combination drug regimens, a heightened emphasis on identifying pathogens early, the broadening of home-based oxygen therapy solutions, and strengthened attention to hospital infection control measures.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp

Which Drivers Are Influencing Long-Term Growth In The Pneumonia Therapeutics Market?

The expanding incidence of pneumonia is anticipated to propel the expansion of the pneumonia therapeutics market in the future. Pneumonia describes an infection of the lungs where air sacs become inflamed, frequently leading to symptoms like coughing, elevated temperature, and troubled respiration. A rise in pneumonia occurrences is attributable to elements including an aging populace, atmospheric contamination, tobacco use, compromised immunity, resistance to antimicrobials, and the dissemination of respiratory illnesses such as COVID-19 or influenza. Therapies for pneumonia are instrumental in combating the underlying agents of infection, including bacteria, viruses, or fungi, employing specific medications, and simultaneously aiding recuperation via oxygen support, anti-inflammatory medicines, and control of symptoms. For illustration, in January 2023, data from the National Center for Biotechnology Information, a US-based government agency, indicated that globally, pneumonia impacts about 120 million people annually, leading to approximately 1.3 million deaths. Almost 80% of pediatric pneumonia deaths are observed in children under 2 in developing countries. Consequently, the escalating incidence of pneumonia is fueling the growth of the pneumonia therapeutics market.

How Is The Pneumonia Therapeutics Market Divided Into Segments?

The pneumonia therapeutics market covered in this report is segmented –

1) By Product: Drugs, Vaccine, Oxygen Therapy

2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids

2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines

3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation

What Trends Are Driving The Growth Trajectory Of The Pneumonia Therapeutics Market?

Major companies engaged in the pneumonia therapeutics market are concentrating on developing innovative drug formulations and treatment strategies, such as antibiotic medications, to address antibiotic resistance and better patient outcomes. An antibiotic drug is defined as a type of medication specifically formulated to combat bacterial infections. For instance, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, also an India-based pharmaceutical company, to introduce cefepime-enmetazobactam. This antibiotic combination is employed in treating complex infections, including UTIs and pneumonia, particularly those that exhibit resistance to other medications. It aids in combating bacterial resistance, thereby ensuring effective treatment while reducing the reliance on more powerful antibiotics.

Which Major Industry Participants Are Leading The Pneumonia Therapeutics Market Growth?

Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Pneumonia Therapeutics Market?

North America was the largest region in the pneumonia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pneumonia Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21258&type=smp

Browse Through More Reports Similar to the Global Pneumonia Therapeutics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Anti Infective Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Lower Respiratory Tract Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/lower-respiratory-tract-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795